Postpartum Hemorrhage and Alterations in Uterine Ecostructure
NCT ID: NCT06781528
Last Updated: 2025-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2021-06-10
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Ultrasonographic Parameters With FIGO Clinical Grading System for Placenta Accreta Spectrum
NCT04801706
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
NCT06898034
Frequency of Isthmocele Following Single- Vs Double-layer Uterine Closure.
NCT06708234
The Role of Ultrasonography in Labor in Predicting the Outcomes of Childbirth
NCT06806904
Uterine Doppler As StillbirthPredictor
NCT06825481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are currently few studies in the literature on the topic, and those that do exist report conflicting results on the association between JZ alterations and risk of postpartum hemorrhage. Altered uterine contractile capacity and abnormal trophoblastic invasion of the myometrial endometrial junctional zone are the mechanisms called into question that could explain the increased risk of postpartum hemorrhage in patients. With this background, the purpose of our study is to highlight whether the presence of poor definition of the endometrial/myometrial junction, its thickening, or the presence in its context of irregularities and discontinuities represent a risk factor associated with the development of postpartum hemorrhage or are uterine ecostructural changes that develop consequent to a postpartum hemorrhage event.
All patients will be recruited during the puerperium stay at the Division of Obstetrics and Prenatal Age Medicine at Sant'Orsola Polyclinic. Subsequently, women will undergo gynecological examination and transvaginal ultrasound 6-12 months after delivery at the outpatient clinics of the same division.
In addition to the standard transvaginal gynecologic examination and ultrasonography, a 3D evaluation of the uterus and the endometrium-myometrium junctional zone will be performed using a Voluson E8 ultrasound machine (GE, Milan, Italy). This assessment will be quick and painless for the patient and it will last a maximum of five minutes.
For each patient, information will be collected on:
* Age
* Ethnicity
* Body mass index (BMI)
* Relevant pathologies
* Previous uterine surgery (myomectomy, CT scan, OCR)
* Associated symptoms: Dysmenorrhea, Chronic pelvic pain, Pain on ovulation, Dyspareunia, Dysuria, Dyschezia, Alterations in alvus, Abdominal bloating, Abnormal uterine bleeding (menometrorrhagia or spotting)
* Presence of uterine fibroids
* Presence of pelvic endometriosis
* Parity
* Mode of pregnancy onset (spontaneous vs. medically assisted procreation)
* Multiple pregnancy
* Any placental pathologies: placenta previa, accretism, suspected or established detachment.
* Any pathologies arising in pregnancy: gestational hypertension, preclampsia, diabetes
* Gestational age at the time of delivery
* Mode of delivery (vaginal/caesarean section)
* Neonatal weight
* Possible cervical, vulvo-vaginal tears.
* Abnormalities of secondment
* Uterine ultrasound features (classification according to MUSA study)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hemorrhagic participants
Participants who deliver at the Division of Obstetrics and Prenatal Age Medicine at Sant'Orsola Polyclinic by vaginal delivery or cesarean section complicated by primary postpartum hemorrhage.
Ultrasound evaluation
All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
No hemorrhagic participants
Participants who deliver at the Division of Obstetrics and Prenatal Age Medicine of Sant'Orsola Polyclinic by vaginal delivery or cesarean section not complicated by postpartum hemorrhage or other adverse obstetrical events matched for gestational age and parity at delivery.
Ultrasound evaluation
All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound evaluation
All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acquisition of Informed Consent Form
* Primary postpartum hemorrhage (defined as blood loss greater than or equal to 1 liter or blood loss that is accompanied by signs and symptoms of hypovolemia occurring within 24 hours of delivery)
* Age \> 18 years
* Acquisition of Informed Consent Form
* Delivery not complicated by postpartum hemorrhage or other adverse obstetric events
Exclusion Criteria
* Presence of pelvic endometriosis
* Maternal hypertensive conditions
* Pluriparity (\> 3)
* Multiple pregnancy
* Polydramnios
* Obesity (BMI\> 35)
* Neonatal macrosomia
* Known coaugulopathies/thrombocytopenias
* Refusal to undergo subsequent follow-up at our center
18 Years
44 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gianluigi Pilu, MD
Role: PRINCIPAL_INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPP1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.